Open access · CC-BY
via OpenAlex
mTOR signaling and Alzheimer's disease: What we know and where we are?
Samin Davoody, Afsaneh Asgari Taei, Pariya Khodabakhsh, Leila Dargahi
CNS Neuroscience & Therapeutics · 2023 · ▲ 97 citations
Deregulated nutrient-sensing
Altered intercellular communication
Disabled macroautophagy
Rapamycin / mTOR inhibition
Human
Review
Abstract
Despite the great body of research done on Alzheimer's disease, the underlying mechanisms have not been vividly investigated. To date, the accumulation of amyloid-beta plaques and tau tangles constitutes the hallmark of the disease; however, dysregulation of the mammalian target of mTOR(definition)-inhibiting drug studied for extending healthspan and lifespan." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">rapamycin(definition) (mTOR) seems to be significantly involved in the pathogenesis of the disease as well. mTOR, as a serine-threonine protein kinase, was previously known for controlling many cellular functions such as cell size, autophagy(definition), and metabolism. In this regard, mammalian target of rapamycin complex 1 (mTORC1) may leave anti-aging impacts by robustly inhibiting autophagy, a mechanism that inhibits the accumulation of damaged protein aggregate and dysfunctional organelles. Formation and aggregation of neurofibrillary tangles and amyloid-beta plaques seem to be significantly regulated by mTOR signaling. Understanding the underlying mechanisms and connection between mTOR signaling and AD may suggest conducting clinical trials assessing the efficacy of rapamycin, as an mTOR inhibitor drug, in managing AD or may help develop other medications. In this literature review, we aim to elaborate mTOR signaling network mainly in the brain, point to gaps of knowledge, and define how and in which ways mTOR signaling can be connected with AD pathogenesis and symptoms.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1111/cns.14463
- Canonical
- link ↗
- Fetched
- 2026-11-07 MST
Cite this
APA
Davoody, S., Taei, A.A., Khodabakhsh, P., & Dargahi, L. (2023). mTOR signaling and Alzheimer's disease: What we know and where we are?. <em>CNS Neuroscience & Therapeutics</em>. https://doi.org/10.1111/cns.14463
Vancouver
Davoody S, Taei AA, Khodabakhsh P, Dargahi L. mTOR signaling and Alzheimer's disease: What we know and where we are?. CNS Neuroscience & Therapeutics. 2023. doi:10.1111/cns.14463.
BibTeX
@article{samin2023mTORsi,
title = {mTOR signaling and Alzheimer's disease: What we know and where we are?},
author = {Samin Davoody and Afsaneh Asgari Taei and Pariya Khodabakhsh and Leila Dargahi},
journal = {CNS Neuroscience & Therapeutics},
year = {2023},
doi = {10.1111/cns.14463},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Autophagy 2023
Preprint · OA
Rapamycin and Alzheimer disease: a hypothesis for the effective use of rapamycin for treatment of neurodegenerative disease
PLoS ONE 2010
Open access · CC-BY
Dysregulation of the mTOR Pathway Mediates Impairment of Synaptic Plasticity in a Mouse Model of Alzheimer's Disease
Journal of neural transmission. Supplementum 1998
Citation only
Free radicals in Alzheimer’s disease
Pharmaceuticals 2019
Open access · CC-BY
Cellular Senescence and Iron Dyshomeostasis in Alzheimer’s Disease
Alzheimer s & Dementia 2011
Citation only
P2‐301: The mTOR pathway in Alzheimer's disease
The Journals of Gerontology Series A 2009
Open access · OA